France· FR:67881720
JAYPIRCA 100 mg, comprimé pelliculé
A pirtobrutinib product containing pirtobrutinib, registered in France by ELI LILLY NEDERLAND BV (PAY-BAS), on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Pirtobrutinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EL05 (pirtobrutinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Pirtobrutinib · ATC L01EL05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pirtobrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.20 in France to $369.10 in Switzerland — a ×1801 gap.
- France: $0.20 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Pirtobrutinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$369.10
- FR France$0.20
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PIRTOBRUTINIB
- Manufacturer
- ELI LILLY NEDERLAND BV (PAY-BAS)
- Country
- France (FR)
- ATC code
- L01EL05
- ATC class
- Pirtobrutinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930276457plaquette(s) thermoformée(s) polychlortrifluoroéthylène PVC aluminium de 60 comprimé(s)EUR 5.4
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pirtobrutinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJAYPIRCAEli Lilly Nederland B.V., Utrecht
- SwitzerlandJaypirca
- FinlandJaypircaEli Lilly Nederland B.V
- IrelandJaypirca 100 mg film-coated tabletsEli Lilly Nederland B.V.
- IcelandJaypircaEli Lilly Nederland B.V.*
- NetherlandsJaypirca 100 mg filmomhulde tablettenEli Lilly Nederland B.V.
- NorwayJaypircaEli Lilly Nederland B.V.
- PolandJaypircaEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jaypirca
- Liechtenstein · Jaypirca
- Norway · Jaypirca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/446a07c9-b896-4a44-b2c0-e8014d140f51 GET /v1/drugs/446a07c9-b896-4a44-b2c0-e8014d140f51?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67881720",
"date_amm": "2023-10-30",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1738",
"substance": "PIRTOBRUTINIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about pirtobrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.